| scholarly article | Q13442814 |
| P2093 | author name string | E Fang | |
| D Morris | |||
| S Flanagan | |||
| T C Marbury | |||
| P Prokocimer | |||
| S L Minassian | |||
| H W Alcorn | |||
| R Ponnuraj | |||
| P2860 | cites work | Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease | Q36634909 |
| Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations | Q36934733 | ||
| Altered nonrenal drug clearance in ESRD. | Q37305305 | ||
| Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury | Q37336958 | ||
| Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis | Q37461431 | ||
| Tedizolid (TR-701): a new oxazolidinone with enhanced potency | Q37983130 | ||
| Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate | Q38171760 | ||
| Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial | Q38456150 | ||
| Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial | Q42211543 | ||
| Are postoperative complications more common following colon and rectal surgery in patients with chronic kidney disease? | Q43447951 | ||
| Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. | Q44964478 | ||
| Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient | Q46878735 | ||
| Drugs and the liver | Q77495496 | ||
| The effect of chronic renal failure on drug metabolism and transport | Q81742838 | ||
| Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines | Q26829316 | ||
| Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections | Q26853612 | ||
| Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary | Q27026853 | ||
| Prevalence of chronic kidney disease in the United States | Q29614191 | ||
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections | Q33347869 | ||
| Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction | Q33389145 | ||
| Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy | Q33393128 | ||
| Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery | Q33393306 | ||
| Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients | Q33394332 | ||
| Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. | Q33401050 | ||
| Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. | Q33423441 | ||
| New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance | Q34242777 | ||
| Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. | Q34529205 | ||
| Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug | Q34548251 | ||
| Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate | Q34557258 | ||
| Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q34910366 | ||
| Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children | Q35172852 | ||
| Pharmacokinetics of linezolid in subjects with renal dysfunction | Q35685516 | ||
| Infectious complications in chronic kidney disease | Q36525191 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| tedizolid | Q7825683 | ||
| P304 | page(s) | 6471-6476 | |
| P577 | publication date | 2014-08-18 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment | |
| P478 | volume | 58 |
| Q47611899 | Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones |
| Q39067666 | Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections |
| Q47396324 | Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options). |
| Q38777085 | Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones |
| Q38687467 | Mycobacterium abscessus Complex - a Particular Challenge in the Setting of Lung Transplantation. |
| Q41675300 | New antibiotics prior to approval: is this the end of the innovative stagnation? |
| Q28083116 | New developments in the management of severe skin and deep skin structure infections - focus on tedizolid |
| Q37119083 | Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis |
| Q38363223 | Novel antibiotics: are we still in the pre-post-antibiotic era? |
| Q33438834 | Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections |
| Q40210571 | Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects |
| Q47833934 | Pharmacokinetics of tedizolid in obese patient after bariatric surgery: a case report |
| Q50104909 | Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects |
| Q35542330 | Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections |
| Q43966214 | Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity. |
| Q59882686 | Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series |
| Q42797201 | Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight |
| Q36327804 | Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration |
| Q33420646 | Tedizolid Phosphate: a Next-Generation Oxazolidinone |
| Q38554583 | Tedizolid for treatment of acute bacterial skin and skin structure infections |
| Q41996895 | Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease |
| Q34596353 | Tedizolid population pharmacokinetics, exposure response, and target attainment |
| Q38352171 | Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. |
| Q38347869 | Therapeutic options for vancomycin-resistant enterococcal bacteremia. |
| Q49446863 | Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention |
Search more.